logo
ENع
#

Latest news with #JoaquinDuato

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Yahoo

time4 days ago

  • Business
  • Yahoo

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

NEW BRUNSWICK, N.J., May 28, 2025--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website A replay of the webcast will be available approximately three hours after the conference call concludes. By telephone: for both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261. A replay of the conference call will be available until approximately 12:00 a.m. on July 30th. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13754017. The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call. Please refer to for a complete list of currently planned earnings webcast/conference calls. Please note the third-quarter date of Tuesday, October 14th, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at View source version on Contacts Media contact:media-relations@ Investor contact: investor-relations@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations
JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations

Yahoo

time23-04-2025

  • Business
  • Yahoo

JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 2.4% year on year to $21.89 billion. The company's full-year revenue guidance of $92 billion at the midpoint came in 1.8% above analysts' estimates. Its non-GAAP profit of $2.77 per share was 7.3% above analysts' consensus estimates. Is now the time to buy JNJ? Revenue: $21.89 billion vs analyst estimates of $21.56 billion (2.4% year-on-year growth, 1.5% beat) Adjusted EPS: $2.77 vs analyst estimates of $2.58 (7.3% beat) Adjusted EBITDA: $9.16 billion vs analyst estimates of $8.39 billion (41.8% margin, 9.2% beat) The company slightly lifted its revenue guidance for the full year to $92 billion at the midpoint from $91.3 billion Management reiterated its full-year Adjusted EPS guidance of $10.60 at the midpoint Operating Margin: 28.3%, in line with the same quarter last year Free Cash Flow Margin: 43.2%, up from 13.3% in the same quarter last year Organic Revenue rose 3.3% year on year (5.2% in the same quarter last year) Market Capitalization: $380.2 billion Johnson & Johnson's latest quarter was shaped by ongoing growth in its innovative medicine and MedTech segments, as highlighted on the company's earnings call. CEO Joaquin Duato cited 4.2% operational sales growth in innovative medicine, despite the negative impact from biosimilar competition for STELARA, and emphasized the company's strong product launches and portfolio diversification. MedTech's growth was supported by contributions from recent acquisitions and new product introductions, offsetting short-term headwinds in orthopedics and procedure volumes. Looking ahead, management identified 2025 as a catalyst year, focusing on expanding key brands, advancing the pipeline, and executing on recently closed acquisitions. The company reaffirmed its full-year adjusted earnings guidance, while CFO Joe Wolk said the updated revenue outlook incorporates the addition of Caplyta from the IntraCellular acquisition. Management flagged the importance of mitigating new tariffs, navigating the loss of exclusivity for major products, and sustaining growth from its expanding medicine pipeline. Johnson & Johnson's management attributed the quarter's outperformance to both resilience in innovative medicine and robust execution in MedTech. Their remarks underscored the effects of biosimilar competition, new product launches, and strategic investments: STELARA biosimilar headwinds managed: Despite anticipated declines from biosimilar competition and U.S. Medicare Part D redesign, management emphasized that operational sales growth in innovative medicine was driven by double-digit expansion in eleven core brands, with Tremfya and DARZALEX noted for strong demand. Key launches in immunology and oncology: Tremfya's new indications in inflammatory bowel disease and Crohn's disease accelerated growth. Meanwhile, expanded European approval and new data for DARZALEX and riboflavin plus LASCRUZ in oncology highlighted the pipeline's contribution to sales. MedTech growth from acquisitions and new products: The acquisitions of Abiomed and Shockwave were cited as meeting expectations and broadening the MedTech portfolio. Newly launched devices, such as the Javelin Peripheral IVL catheter and expanded robotic surgery trials, contributed to segment growth. Operational and margin pressures addressed: Management discussed cost pressures from product mix, tariffs, and acquisition-related expenses, but pointed to spending discipline and a restructuring program in surgery as measures to improve profitability by 2027. Capital allocation and investment priorities: The company reiterated its commitment to R&D, announcing plans to invest over $55 billion in U.S. manufacturing and technology over four years, alongside a dividend increase for the sixty-third consecutive year. Management's outlook for 2025 anticipates operational sales growth between 3.3% and 4.3% (midpoint $92 billion) and maintains adjusted earnings per share guidance at a midpoint of $10.60, as the company integrates new assets and navigates market headwinds. Pipeline and new indications: The expansion of Tremfya, Caplyta, and upcoming filings for Ichotrochindra in autoimmune diseases are expected to offset the impact of lost exclusivity in other key products, supporting revenue growth. Tariffs and margin management: Newly imposed tariffs, particularly affecting MedTech exports to China, present a $400 million headwind; management is pursuing production shifts and advocating for favorable tax policies to mitigate this impact. MedTech portfolio optimization: Restructuring and exiting non-strategic product lines, combined with investment in higher-growth devices, are expected to support longer-term margin improvement and segment growth. Larry Biegelsen (Wells Fargo): Asked about the $400 million tariff impact and mitigation strategies; management said tariffs primarily hit MedTech exports to China and are seeking production adjustments rather than price increases. Chris Schott (JPMorgan): Inquired about gross margin drivers; CFO Joe Wolk cited product mix, STELARA's decline, and currency headwinds, and noted that consensus estimates were likely too optimistic. Asad Hader (Goldman Sachs): Requested quantitative detail on STELARA biosimilar erosion; management reiterated guidance based on the HUMIRA precedent and emphasized offsetting growth in other brands. Joanne Wuensch (Citibank): Questioned the orthopedics segment's underperformance and recovery timeline; management acknowledged competitive pressures and expected innovation and new launches to drive improvement. Matt Miksic (Barclays): Sought clarity on immunology opportunities, especially for Tremfya and Ichotrochindra; executives highlighted strong initial launches and market expansion potential for both products. In coming quarters, the StockStory team will be monitoring (1) the rollout and uptake of new indications for Tremfya and Caplyta, (2) the pace of MedTech's margin improvement and execution of the surgery restructuring plan, and (3) progress on upcoming regulatory submissions and product launches, especially for Ichotrochindra in autoimmune diseases. The handling of tariffs and biosimilar competition will also be key themes to watch. Could JNJ achieve its goals and exceed our expectations? See for yourself in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio

Trade war shock hits US companies
Trade war shock hits US companies

The Hill

time16-04-2025

  • Business
  • The Hill

Trade war shock hits US companies

Thank you for signing up! Subscribe to more newsletters here AMERICAN COMPANIES ARE WARNING of multibillion-dollar setbacks and extreme uncertainty over the trade war with China as earnings season gets underway. United Airlines gave two financial forecasts, saying it's 'impossible to predict' whether the U.S. might slide into a recession amid the tit-for-tat tariffs. Johnson & Johnson CEO Joaquin Duato warned the trade war may disrupt the drug supply chain as the administration considers new tariffs on pharmaceuticals. Treasury Secretary Scott Bessent said in an interview with Yahoo Finance that CEOs should stop worrying. 'We're going to have a lot more clarity on the way forward over the next 90 days,' Bessent said. CHIPMAKERS TAKE A HIT U.S.-based artificial intelligence chipmakers are taking massive hits over a new Trump administration rule meant to keep China from building a supercomputer. Nvidia's stock plunged nearly 7 percent Wednesday after the company announced it would take a $5.5 billion quarter charge tied to its chip exports to China. The California-based company revealed in a filing that the U.S. government will require it to obtain a license to export some chips due to new restrictions. Similarly, Advanced Micro Devices said it would incur expenses of $800 million due to the new export control licensing requirements. The Trump rule has some bipartisan support. The Hill's Miranda Nazzaro reports: 'Sen. Elizabeth Warren (D-Mass.), ranking member of the Senate Committee on Banking, Housing and Urban Affairs, wrote to Commerce Secretary Howard Lutnick to push for restrictions on exports of the H20 chip and others to China. She argued Nvidia's continued export of the chip will work against Trump's goal of bringing manufacturing to the United States.' The stock indices continued their recent wild swings with a drop on Wednesday, led by a tech sector sell-off. POWELL WARNS OF INFLATION, SLOWER GROWTH Federal Reserve Chairman Jerome Powell said Wednesday in a speech at the central bank that he's monitoring potential inflationary and growth pressures on the economy due to the trade war. 'Tariffs are highly likely to generate at least a temporary rise in inflation,' Powell said. 'The level of the tariff increases announced so far is significantly larger than anticipated,' he added. 'The same is likely to be true of the economic effects, which will include higher inflation and slower growth.' The World Trade Organization (WTO) called the global trade war a 'crisis' and warned of economic disaster if 'the situation deteriorates.' 'Our simulations show that trade policy uncertainty has a significant dampening effect on trade flows, reducing exports and weakening economic activity,' said WTO chief economist Ralph Ossa. 💡Perspectives: • Racket: A reckoning is coming for the private equity economy. • The L.A. Times: Dems must speak to cultural concerns and economics. • The Nation: Why Bernie went to Coachella. • The Wall Street Journal: Trump misunderstands the 'China shock.' • The Hill: To defend democracy, Democrats must listen to red state voters. Read more: • CBP says tariffs generated $500 million, well below Trump's estimate. • Trump launches probe laying groundwork for tariffs on critical minerals. • GOP hopes Supreme Court bails them out on Trump's trade war. • California is first state to sue Trump on tariffs. A third adviser to Defense Secretary Pete Hegseth has been put on leave amid a probe into leaks of information at the Pentagon. The Associated Press is asking a federal judge to intervene following a move by the White House to remove the spot typically reserved for wire services from the press pool covering the president. President Trump and five members of his administration have been named to Time magazine's list of 'the 100 Most Influential People of 2025.' © Manuel Balce Ceneta, Associated Press; Carolyn Van Houten, The Washington Post U.S. District Judge James Boasberg found probable cause to hold Trump administration officials in criminal contempt for disobeying his order to immediately halt deportations under the Alien Enemies Act and turn around any airborne planes. The Hill's Rebecca Beitsch and Zach Schonfeld report: 'Boasberg's order gives the administration a final opportunity to come into compliance but says he otherwise will take steps to identify the specific people who flouted his March 15 ruling, which was later lifted by the Supreme Court, and refer them for prosecution.' It's the latest in the standoff between the Trump administration and the courts over President Trump's aggressive deportation efforts, which ensnared Kilmar Abrego Garcia, who was the subject of a clerical error that sent him to a prison in El Salvador. An immigration judge had previously ruled that Garcia should not be sent back to his home country for safety reasons. At a Tuesday hearing, a different federal judge ordered depositions be taken from several Trump officials, saying they failed to take the necessary steps to secure Garcia's return. The Trump administration says it has no authority to bring Garcia back. They claim he's a gang member, although Garcia's attorneys deny this. The Department of Homeland Security on Wednesday released court documents alleging Garcia's wife sought a restraining order against him over allegations of domestic abuse. 'This MS-13 gang member is not a sympathetic figure,' the agency posted on X. Garcia has been living in Maryland, where he married a U.S. citizen and has three children. The Supreme Court ruled 9-0 that the government must 'facilitate' Garcia's return to the U.S., although they said the courts likely couldn't force the government to 'effectuate' his return. Legal experts believe the high court will have to rule again on the matter. Sen. Chris Van Hollen (D-Md.) traveled Wednesday to El Salvador to do a wellness check on Garcia, although the government there denied his request to meet or speak with him. Van Hollen said Salvadoran Vice President Félix Ulloa told him the government had no information connecting Garcia to MS-13. 'If the government of El Salvador has no evidence that he was part of MS-13, why is El Salvador continuing to hold him in CECOT?' Van Hollen said at a press conference. It's a fraught political issue that has inflamed debate in Washington. Democrats warn the Trump administration is depriving people of due process, which could lead to further errors and the potential for U.S. citizens to get swept up in the deportations. They're accusing the government of provoking a Constitutional crisis by ignoring court orders. 'If the president has the power to jail, imprison and deport anyone, even if they have a legal right to be here … then none of us are safe,' Sen. Chris Murphy (D-Conn.) said. Republicans, meanwhile, are accusing Democrats and the media of prioritizing the safety of criminal illegal immigrants over U.S. citizens, arguing that Trump was elected in part due to his promises to end the border crisis and crack down on illegal immigration. Vice President Vance on Wednesday argued in a lengthy post on X that it would be impossible to give the millions of immigrants in the country illegally a court trial. 'The American people elected the Trump administration to solve this problem,' Vance said. 'The President has successfully stopped the inflow of illegal aliens, and now we must deport the people who came here illegally.' 💡Perspectives: • The Bulwark: The risk of random, unaccountable detention is growing. • The Washington Examiner: Garcia isn't a winning political issue for Dems. • New York: MAGA's class warfare against knowledge workers is personal. • The Hill: Trump is laughing at the Supreme Court and the Constitution. Read more: • Biden, Obama-appointed judges oversee bulk of Trump cases. • Grassley pressed on wrongly deported man at heated town hall. • As border wars recede, park reopens. • Two service members killed in accident at US-Mexico border. © Greg Nash The latest Yale Youth survey finds former Vice President Harris (D) is the top preference for Democratic voters, but Rep. Alexandria Ocasio-Cortez (D-N.Y.) is on the move. The poll — which over-samples young voters but is weighted for an accurate reflection of the full pool of Democrats — finds Harris leading at 28 percent, followed by Ocasio-Cortez at 21 percent, former Transportation Secretary Pete Buttigieg at 14 percent, California Gov. Gavin Newsom (D) at 6 percent and Pennsylvania Gov. Josh Shapiro (D) at 5 percent. Ocasio-Cortez is proving to be a huge draw on the campaign trail alongside Sen. Bernie Sanders (I-Vt.). The pair drew a reported 30,000 to an event in Folsom, Calif. on Tuesday evening. Ocasio-Cortez raised an astonishing $9.6 million in the first quarter of the year. There has been some buzz around sports commentator Stephen A. Smith, who has criticized Democratic leadership and could have some appeal as an outsider. Smith has kept the door open for a potential run and has been appearing on political talks shows, furthering speculation about his future. 'I hope somebody from the Democratic Party steps up,' he told Fox News Channel's Sean Hannity. While progressives are pulling big crowds at town halls, Republicans are facing blowback from angry Democrats and independents at forums back home. At least six protesters were removed from Rep. Marjorie Taylor Greene's (R-Ga.) town hall in an Atlanta suburb Tuesday evening. Three people were arrested and two were subdued by stun guns. 'I'm not intimidated by the Democrats who tried to shut down my town hall tonight,' Greene posted on X. 'I refused to tolerate their selfish attempts to disrupt an event that was for all of my constituents, not just the ones who could make the most noise,' she continued. 'This is the type of business that should be handled at the voting booth.' Rep. Brian Mast's (R-Fla.) town hall in Jupiter Farms also got rowdy, as pro-Trump attendees sparred with the anti-Trump crowd. Four members of the audience got into a pushing match, according to the Palm Beach Post. MEANWHILE… The suspect accused of the arson attack on Shapiro's home cited the plight of Palestinians as his motivation, according to a probable cause affidavit filed by the Pennsylvania State Police. Attorney General Pam Bondi says the federal government is assisting with the investigation. 💡Perspectives: • The Washington Post: Have Democrats found their version of Trump? • The Liberal Patriot: Universities have lost public trust. • Harvard Crimson: Harvard must not submit to a hostile takeover. • New York Post: Harvard risks $9 billion with anti-Trump agenda. • The Wall Street Journal: Time for accountability on the Covid lab-leak. Read more: • Musk's tactics to manage his 'Legion' of babies—and their mothers. • DNC official to spend big to take down fellow Democrats. • TGOP's legal threats sink Democrats' billboard attacks over Medicaid. • Biden says Trump has 'done so much damage' since taking office. • Moderate Republicans draw red line on Medicaid cuts in Trump agenda bill. Someone forward this newsletter to you? Sign up to get your own copy: See you next time!

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store